RayKnowChina Research Map
Shortlist0

Anhui Medical University

安徽医科大学

HefeiUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.2%Leads under 1 in 100 of China's research papers on NPC

Led 4 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 222025
ThemesRadiotherapy techniqueImaging & AISide effects & quality of life

Hospitals counted here

  1. First Affiliated Hospital of Anhui Medical University3
  2. Second Affiliated Hospital of Anhui Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
1.0%Leads under 1 in 100 of China's research papers on ESCC

Led 29 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
0
Research papers it led
29
Trials it led
2
Share of China's trials
0.4%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
ThemesImaging & AIMolecular markers & genomicsSurgery

Hospitals counted here

  1. First Affiliated Hospital of Anhui Medical University23
  2. Anhui Chest Hospital1
  3. Affiliated Bozhou Hospital of Anhui Medical University1
  4. Third Affiliated Hospital of Anhui Medical University Counted in the group total1
  5. Second Affiliated Hospital of Anhui Medical University1
  6. Affiliated Hospital of Anhui Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Radical surgery versus definitive radiotherapy in treatment of locoregional upper esophageal squamous cell carcinoma.2025BMC cancerFree full text
  2. Cervical Incision-Free Technique for R0 Resection in Cervicothoracic Esophageal Carcinoma: A Novel Approach of the Chai's Supra-Thoracic Apex Technique.2025Journal of laparoendoscopic & advanced surgical techniques. Part A
  3. Patterns of Lymph Node Recurrence after Esophagectomy of pT2-3 N0M0 Esophageal Squamous Cell Carcinoma.2025Journal of gastrointestinal cancerFree full text
  4. Correlative analysis of immune-related thyroid dysfunction and prognosis in patients with advanced esophageal squamous cell carcinoma.2025Anti-cancer drugs
  5. Radiomics and prognostic nutritional index for predicting postoperative survival in esophageal carcinoma.2025European journal of medical researchFree full text
Trials on ClinicalTrials.gov6
  1. Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT07787273Study sitePhase 2Start 2026-03
  2. Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)RecruitingNCT06780111Study sitePhase 1/Phase 2Start 2025-07
  3. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  4. Lymph Node Metastasis in Early Esophageal Squamous Cell CarcinomaStatus unknownNCT07050576Lead sponsorStart 2024-05
  5. Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard TreatmentStatus unknownNCT03224221Lead sponsorPhase 2Start 2017-03
  6. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Study sitePhase 2Start 2023-11

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
1.2%Leads about 1 in 80 of China's research papers on HCC

Led 184 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
0
Research papers it led
184
Trials it led
2
Share of China's trials
0.1%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 332025
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Anhui Medical University101
  2. Second Affiliated Hospital of Anhui Medical University27
  3. Affiliated Bozhou Hospital of Anhui Medical University5
  4. Fuyang Hospital, Anhui Medical University Counted in the group total4
  5. Fourth Affiliated Hospital of Anhui Medical University Counted in the group total3
  6. Affiliated Chuzhou Hospital of Anhui Medical University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Genetically engineered pig-to-human liver xenotransplantation.2026Journal of hepatology
  2. Comparative effectiveness and safety of second-line therapies and dosing regimens for advanced hepatocellular carcinoma: a network meta-analysis.2026European journal of gastroenterology & hepatologyFree full text
  3. Development and validation of a nomogram model for predicting acute hepatic dysfunction post-intervention in primary hepatocellular carcinoma: a retrospective case-control study.2025World journal of surgical oncologyFree full text
  4. Efficacy and Safety of Microwave Ablation in Patients With Hepatocellular Carcinoma With Decompensated Liver Cirrhosis: A Retrospective Study.2025Canadian journal of gastroenterology & hepatologyFree full text
  5. Multi-modality model predicts lung metastasis of hepatocellular carcinoma using MRI and pathological: a retrospective multicenter study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Trials on ClinicalTrials.gov6
  1. NK521 in the Treatment of Advanced Solid TumorsNot yet recruitingNCT07657416Study siteEarly phase 1Start 2027-01
  2. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCCRecruitingNCT07547553Study sitePhase 1/Phase 2Start 2026-05
  3. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  4. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  5. Comparison of Gd-EOB-DTPA-enhanced MRI and Contrast-enhanced Ultrasound for Measuring Tumor Size of Solitary Hepatocellular Carcinoma ≤ 5cm:A Retrospective StudyCompletedNCT06437457Lead sponsorStart 2019-01
  6. Impact of Hepatectomy on HCC RecurrenceCompletedNCT06390228Lead sponsorStart 2019-01

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
1.4%Leads about 1 in 74 of China's research papers on Stomach cancer

Led 132 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
0
Research papers it led
132
Trials it led
4
Share of China's trials
0.3%
Share of the world's papers
0.6%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 2220242025: 112025
ThemesImaging & AIPeritoneal spread & advanced diseaseSurgery

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Anhui Medical University84
  2. Second Affiliated Hospital of Anhui Medical University21
  3. Fourth Affiliated Hospital of Anhui Medical University Counted in the group total3
  4. Chaohu Hospital, Anhui Medical University3
  5. First People's Hospital of Anhui Medical University2
  6. Affiliated Chuzhou Hospital of Anhui Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Effect of Behavioral Activation on Stigma and Quality of Life in Patients With Advanced Esophageal and Gastric Cancer: A Randomized Controlled Trial.2024Psycho-oncologyRCT
  2. Impacts and Pathways of Behavioral Activation on Psychological Distress Among Patients Diagnosed With Esophageal and Gastric Cancer in China: A Randomized Controlled Trial.2024Cancer medicineRCTFree full text
  3. Efficacy and safety of esophageal submucosal tumors treated with internal traction method-assisted submucosal tunneling endoscopic resection: a single-center, single-blind, randomized controlled study.2023Surgical endoscopyRCT
  4. Prognostic value of different lymph node staging methods for node-positive cardia gastric cancer: a register-based retrospective cohort study.2021BMJ openRCTFree full text
  5. Timing of Adjuvant Chemotherapy After Gastrectomy in Patients With Stage II to III Gastric Cancer: A Target Trial Emulation Study.2025JCO precision oncology
Trials on ClinicalTrials.gov6
  1. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  2. Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)RecruitingNCT07401199Study siteStart 2026-02
  3. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  4. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  5. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsRecruitingNCT04900818Study sitePhase 1Start 2021-06
  6. Capecitabine or Observation for Patients With pT1N+M0 or pT2-3N0M0 Gastric Adenocarcinoma Undergoing R0 ResectionStatus unknownNCT03817268Lead sponsorPhase 3Start 2019-01

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
1.0%Leads under 1 in 100 of China's research papers on Osteosarcoma

Led 22 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
22
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 222025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
0.4%Leads under 1 in 100 of China's research papers on Gastrointestinal stromal tumour New since 2021

Led 2 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Second Affiliated Hospital of Anhui Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.4%Leads under 1 in 100 of China's research papers on Neuroblastoma

Led 4 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.09%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 332025

Hospitals counted here

  1. Second Affiliated Hospital of Anhui Medical University2
  2. Fuyang Hospital, Anhui Medical University1
  3. First Affiliated Hospital of Anhui Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
1.2%Leads about 1 in 81 of China's research papers on Ewing sarcoma New since 2021

Led 2 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Anhui Medical University1
  2. Second Affiliated Hospital of Anhui Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
1.2%Leads about 1 in 84 of China's research papers on Myeloma ▲ from 0.3%

Led 20 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
20
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 222025
ThemesDiagnosis, MRD & riskDrug combinationsKidney & bone complications

Hospitals counted here

  1. First Affiliated Hospital of Anhui Medical University10
  2. Second Affiliated Hospital of Anhui Medical University7
  3. Suzhou Hospital, Anhui Medical University Counted in the group total1
  4. Affiliated Fuyang People's Hospital of Anhui Medical University1
  5. Anqing Municipal Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. IPD regimen effect on the levels of VEGF and IL-6 in elderly patients with recurrent multiple myeloma.2025Indian journal of cancerRCT
  2. Systemic lupus erythematosus associated with multiple myeloma: Two case reports and a literature review.2023Immunity, inflammation and diseaseFree full text
  3. Acupuncture-exacerbated pyoderma gangrenosum associated with IgG multiple myeloma.2022Wounds : a compendium of clinical research and practice
  4. WTAP promotes the proliferation of multiple myeloma by regulating the hippo pathway through m6A modification of MAP6D1.2026Leukemia & lymphoma
  5. CBX7 regulates chemotherapy-induced senescence-like growth arrest in multiple myeloma via the ERK/STAT3/PIM1 axis.2025Journal of translational medicineFree full text
Trials on ClinicalTrials.gov5
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  2. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  3. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  4. Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid TherapyCompletedNCT02609828Study sitePhase 3Start 2015-10
  5. Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)TerminatedNCT01947309Study siteStart 2013-11

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
1.8%Leads about 1 in 56 of China's research papers on B-ALL ▲ from 1.0%

Led 4 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025
ThemesCAR-T & cell therapyChildrenMRD & relapse

Hospitals counted here

  1. Second Affiliated Hospital of Anhui Medical University4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
1.0%Leads under 1 in 100 of China's research papers on Aplastic anaemia ▲ from 0.4%

Led 4 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 0020242025: 002025
ThemesStem cell transplantImmunosuppressive treatmentChildren

Hospitals counted here

  1. First Affiliated Hospital of Anhui Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
1.2%Leads about 1 in 80 of China's research papers on HLH

Led 5 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 222025
ThemesEBV & infection triggersGenetics & inherited formsDiagnosis & prognosis

Hospitals counted here

  1. Second People's Hospital, Anhui Medical University1
  2. Second Affiliated Hospital of Anhui Medical University1
  3. First Affiliated Hospital of Anhui Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
1.8%Leads about 1 in 54 of China's research papers on Haemophilia A ▲ from 0.7%

Led 5 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 112025

Hospitals counted here

  1. Second Affiliated Hospital of Anhui Medical University4
  2. Affiliated Provincial Hospital of Anhui Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜
4.7%Leads about 1 in 21 of China's research papers on Thrombotic thrombocytopenic purpura New since 2021

Led 3 of 64 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Anhui Medical University2
  2. Second Affiliated Hospital of Anhui Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led3
  1. Acquired immune thrombotic thrombocytopenic purpura (TTP) associated with inactivated COVID-19 vaccine CoronaVac.2024Frontiers of medicine
  2. Novel ADAMTS13 mutations in a patient with congenital thrombotic thrombocytopenic purpura.2023Hematology (Amsterdam, Netherlands)
  3. A case report of systemic lupus erythematosus presented as thrombotic thrombocytopenic purpura and successfully treated with plasmapheresis and belimumab.2022Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
0.6%Leads under 1 in 100 of China's research papers on NMOSD New since 2021

Led 3 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 112025
ThemesAntibodies & diagnosisBiologic drugsRelapse prevention

Hospitals counted here

  1. Second Affiliated Hospital of Anhui Medical University2
  2. First Affiliated Hospital of Anhui Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgG4-related disease

IgG4相关性疾病
0.8%Leads under 1 in 100 of China's research papers on IgG4-RD

Led 2 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.1%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025
ThemesDiagnosis & look-alikes

Hospitals counted here

  1. First Affiliated Hospital of Anhui Medical University Counted in the group total1
  2. Second Affiliated Hospital of Anhui Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
1.2%Leads about 1 in 83 of China's research papers on Myasthenia gravis

Led 6 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 442025
ThemesThymus & thymectomyAntibodies & diagnosisBiologic & complement drugs

Hospitals counted here

  1. First Affiliated Hospital of Anhui Medical University4
  2. Suzhou Hospital, Anhui Medical University Counted in the group total1
  3. Third Affiliated Hospital of Anhui Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Wilson disease

肝豆状核变性(Wilson 病)
0.5%Leads under 1 in 100 of China's research papers on Wilson disease ▼ from 6.2%

Led 1 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.5%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025
ThemesGenetics (ATP7B)Brain & movement symptoms

Hospitals counted here

  1. First Affiliated Hospital of Anhui Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
2.6%Leads about 1 in 38 of China's research papers on Anti-NMDA receptor encephalitis New since 2021

Led 7 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 222025

Hospitals counted here

  1. First Affiliated Hospital of Anhui Medical University7

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Takayasu arteritis

大动脉炎
1.1%Leads about 1 in 93 of China's research papers on Takayasu arteritis New since 2021

Led 2 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (24.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Anhui Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
1.0%Leads about 1 in 99 of China's research papers on Idiopathic pulmonary fibrosis

Led 10 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
10
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025

Hospitals counted here

  1. First Affiliated Hospital of Anhui Medical University5
  2. Second Affiliated Hospital of Anhui Medical University4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
1.9%Leads about 1 in 53 of China's research papers on IgA nephropathy ▲ from 0.3%

Led 14 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
14
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.8%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of Anhui Medical University11
  2. Chaohu Hospital, Anhui Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
1.3%Leads about 1 in 75 of China's research papers on Primary biliary cholangitis ▲ from 0.7%

Led 4 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 222025

Hospitals counted here

  1. First Affiliated Hospital of Anhui Medical University3
  2. Second Affiliated Hospital of Anhui Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary sclerosing cholangitis

原发性硬化性胆管炎
2.0%Leads about 1 in 50 of China's research papers on Primary sclerosing cholangitis New since 2021

Led 2 of 100 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

Hospitals counted here

  1. First Affiliated Hospital of Anhui Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症
3.6%Leads about 1 in 28 of China's research papers on Inherited epidermolysis bullosa ▼ from 4.8%

Led 2 of 56 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.5%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of Anhui Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov